In the July 8, 2014, Federal Register, FDA announced a public meeting and opportunity for public comment on Patient-Focused Drug Development for idiopathic pulmonary fibrosis. In the July 9, 2014, Federal Register, FDA announced a public meeting and opportunity for public comment on Patient-Focused Drug Development for Hemophilia A, Hemophilia B, von Willebrand Disease, and other heritable bleeding disorders. Patient-Focused Drug Development is one of the Agency's performance commitments as provided by the fifth authorization of the Prescription Drug User Fee Act. The meetings are intended to allow FDA to collect patient perspectives on the impact of and treatment approaches for these disorders. The public meeting on Idiopathic Pulmonary Fibrosis will be held on September 26, 2014; comments are due November 26, 2014. The public meeting on heritable bleeding disorders will be held on September 22, 2014; comments are due November 28, 2014.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
